Personalized glycemic response led digital therapeutics program improves time in range in a period of 14 days.

Autor:	Verma, Ritika, Bhardwaj, Shefali, Lathia, Tejal, Kalra, Sanjay, Ranadive, Ruchira, Tanna, Snehal, Padsalge, Mahesh, Juneja, Archana, Samundra, Kirti, Thakkar, Piya Ballani, Jain, Vandana, Kini, Vishal, Kothari, Sneha, Guntur, Saimala, Joshi, Shilpa, Singal, Arbinder
Předmět:	BLOOD sugar analysis EVALUATION of human services programs GLYCEMIC control DIGITAL technology TIME BLOOD sugar monitoring INDIVIDUALIZED medicine TYPE 2 diabetes PRE-tests & post-tests HEALTH behavior DESCRIPTIVE statistics RESEARCH funding BEHAVIOR modification SECONDARY analysis
Zdroj:	International Journal of Diabetes in Developing Countries; Jun2023, Vol. 43 Issue 3, p425-432, 8p
Abstrakt:	Background: Lifestyle modification is an integral aspect for the management of type 2 diabetes (T2D). However, it is difficult to ensure the accuracy of personalized lifestyle advice. The study aims to analyse the real-world effectiveness of personalized glycemic response based Diabefly-Pro digital therapeutics for better glycemic control. Methods: Data from continuous glucose monitoring (CGM) of 64 participants with T2D was analysed. All participants were provided with modified lifestyle plan based on their personalized glycemic response. The CGM data was analysed for a period of 7 days, before and after the introduction of modified lifestyle plan. Primary outcome of the study was change in time in range (TIR). Secondary outcomes of the study were change in mean blood glucose, time above range (TAR), time below range (TBR) and glucose management indicator (GMI). Results: Significant improvement in glycemic control was observed after the introduction of personalized lifestyle plan. Median reduction in mean blood glucose was from 139.5 (118.3 to 169.3) mg/dL to 122.0 (101.5 to 148.8) mg/dL (p < 0.0001). TIR and GMI improved from 70.50 (50.75 to 83.50) % to 75.00 (58.25 to 89.00) % (p = 0.0001) and 6.64 (6.13 to 7.35) % to 6.23 (5.74 to 6.86) % (p < 0.0001) respectively. TAR reduced significantly from 17.00 (4.25 to 38.0) % to 6.00 (1.25 to 26.0) % (p < 0.0001). No significant increase in TBR was observed (p = 0.198). Conclusion: Personalized glycemic response-based Diabefly-Pro digital therapeutics program was effective in achieving better glycemic control in people with T2D. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.